SS-31 (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

SS-31 (also catalogued as elamipretide) is a mitochondria-targeted tetrapeptide investigated for its ability to bind cardiolipin in the inner mitochondrial membrane. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed across published research, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 1.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that fill, a single unit on a U-100 insulin syringe corresponds to 0.01 mL and delivers 100 mcg of material, so 50 units equals 5 mg and a full 100 units equals the whole 10 mg vial — arithmetic that stays clean across each titration step.

Standard (Gradual) Titration Schedule

The gradual schedule reflects the daily dosing model used in the published clinical work, where a lower introductory amount is held for the first couple of weeks before stepping up to the working dose to allow injection-site tolerability to settle.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 1.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Aggressive) Titration Schedule

The advanced schedule pushes past the standard 10 mg working dose toward the 15–20 mg daily amounts referenced only under supervision in research contexts. Because a single 10 mg fill tops out at 1.0 mL, doses above 10 mg are split across two injections drawn from two vials.

Supplies Needed

• SS-31 vials (10 mg): ~50 vials for an 8-week run at 5–10 mg/day; ~77 vials for a 12-week run at a 10 mg/day maintenance; ~105 vials for a 12-week advanced run reaching 15 mg/day.
• Insulin syringes (U-100, 1 mL): 7 per week — roughly 56 for an 8-week schedule and 84 for 12 weeks (one fresh syringe per draw).
• Bacteriostatic water (30 mL): two bottles cover ~50 vials over 8 weeks; three bottles for a 77-vial 12-week run; four bottles for a 105-vial advanced run.
• Alcohol swabs: about 14 per week (two per injection); a pair of 100-count boxes comfortably covers an 8–12 week schedule.

Protocol Overview

• Research goal: model mitochondrial bioenergetics by stabilizing the inner-membrane cardiolipin environment and electron transport chain.
• Schedule: once-daily subcutaneous administration in the published model.
• Dose band: 5–10 mg/day standard, up to 15–20 mg/day in advanced (supervised) arms.
• Fill: 10 mg lyophilized, reconstituted to 10 mg/mL with 1 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 5 mg introductory step and hold it for the first two weeks before stepping up to the 10 mg working dose.
• Keep administration on a fixed once-daily cadence, ideally at the same time of day, for steady exposure modelling.
• Advance beyond 10 mg only once injection-site tolerability is well established at the prior step.
• Treat 10 mg/day as the central working dose carrying most of the published functional signal.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F), protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and use within about four weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Split any daily volume above 1.0 mL into two draws rather than overfilling a single syringe.
• Document each draw — date, volume, remaining material — for reproducibility.

How SS-31 Works

SS-31 is a small aromatic-cationic tetrapeptide that selectively accumulates in the inner mitochondrial membrane and binds cardiolipin, the signature phospholipid that scaffolds the respiratory complexes. By stabilizing that membrane architecture, it is reported to help hold the electron transport chain complexes in their functional arrangement, curb the leak of pathological reactive oxygen species, and support more efficient ATP synthesis. Unlike receptor-agonist peptides, its activity is structural and bioenergetic rather than hormonal, which is why the research literature frames it around mitochondrial function rather than appetite or growth signalling.

Reported Benefits & Side Effects

Benefits observed in research

• Stabilization of mitochondrial membranes with improved electron transport chain efficiency.
• Greater ATP output alongside reduced generation of damaging reactive oxygen species.
• Functional gains — such as increased muscle strength and exercise capacity — reported in Barth syndrome cohorts.
• Protective signals in preclinical models of heart failure, neurodegeneration and age-related muscle loss.
• No meaningful shifts in blood pressure, heart rate or routine laboratory panels in the trials.

Side effects reported

• Injection-site reactions are the most common finding — mild-to-moderate redness, itching or transient discomfort, usually resolving within hours.
• Roughly 80% of trial participants experienced mild injection-site reactions.
• No dose-limiting toxicities or serious adverse events were directly attributed to the compound.
• Long-term safety data beyond about 12 weeks remains limited.

Supporting Lifestyle Factors (Research Context)

• Nutrition emphasizing mitochondrial cofactors — B-vitamins, CoQ10, magnesium and alpha-lipoic acid — in the study designs.
• Combined resistance and aerobic activity to stimulate mitochondrial biogenesis.
• Seven to nine hours of quality sleep as a standard recovery control.
• Stress reduction through meditation, breathwork or yoga, and minimized exposure to substances that impair mitochondrial function.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them air-dry fully for 30–60 seconds.
• Draw the dose with a new sterile syringe and clear any air bubbles before administering.
• Insert subcutaneously at a 45–90° angle depending on tissue thickness; inject slowly over 3–5 seconds and pause 5–10 seconds before withdrawing.
• Rotate systematically between sites (abdomen at least 2 inches from the navel, outer thighs, upper arms, upper buttocks), apply gentle pressure without vigorous massage, and dispose of sharps in an approved container.

References

Related Protocols